yartemlea
Generic: narsoplimab-wuug·Code: narsoplimab-wuug
yartemlea: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| OMEROS CORP (OMER) | Approved |
FDA Decisions
Approval1 INDICATIONS AND USAGE YARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is a MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). ( 1 )(OMER)
Frequently asked questions
Who is developing yartemlea?
yartemlea is being developed by OMEROS CORP.
What is yartemlea's latest FDA decision?
The most recent tracked FDA decision for yartemlea is Approval for 1 INDICATIONS AND USAGE YARTEMLEA is indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is a MASP-2 inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). ( 1 ), dated December 23, 2025.
Get deeper analysis on yartemlea
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis